C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2024

This “C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

C-MET Non-Small Cell Lung Cancer Understanding

C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC): Overview

The role of the c-mesenchymal-epithelial transition factor (c-MET) signaling pathway in tumor progression and invasion has been extensively studied. C-MET inhibitors have shown anti-tumor activity in Non-Small Cell Lung Cancer both in preclinical and in clinical trials. However, given the molecular heterogeneity of Non-Small Cell Lung Cancer, it is likely that only a specific subset of Non-Small Cell Lung Cancer patients will benefit from c-MET inhibitors. Emerging data also suggest that MET inhibitors in combination with EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) may have a role in therapy for both EGFR-TKI resistant and EGFR-TKI naïve patients. c-Met is known to be overexpressed, mutated and gene amplified, specifically in NSCLC, and has also been implicated in the development of resistance against other small-molecule inhibitors (e.g. EGFR).

C-mesenchymal-epithelial transition factor (c-MET)
Protein tyrosine kinases, such as c-Met, are a family of oncogenes that regulate important cellular processes, such as differentiation, proliferation, cell cycle, motility, and apoptosis. Hepatocyte growth factor (HGF), a ligand for c-Met, is secreted by mesodermal cells during development. It produces multiple effects upon binding to its receptor (HGFR/c-Met) and regulates proliferation, motility, mitogenesis, and morphogenesis. Mesenchymal-epithelial transition factor (MET) gene can encode unconventional receptor tyrosine kinases with pleiotropic functions, when signals are abnormally activated, it can initiate and maintain tumor transformation, promote cell proliferation, survival, tumor invasion and angiogenesis. Thus, it is a promising therapeutic target.

c-Met inhibitor
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). Many c-Met inhibitors are currently in clinical trials.

Treatment
Although certain phase III clinical trials have failed to meet their endpoints, c-Met inhibitors have the potential to benefit specific subsets of Non-Small Cell Lung Cancer patients on a clinical basis. Therefore, it is extremely important to develop diagnostic testing, and to identify predictive biomarkers, to better determine the benefit of anti-c-Met/HGF therapy. Combinatorial therapies have also proved to be more effective in Non-Small Cell Lung Cancer clinical trials when compared to monotherapies, due to the development of resistance. Overall, further investigation is necessary to move c-Met inhibitors to the final stages of clinical development, in which they have potential to improve the status of NSCLC patients.

Crizotinib received accelerated approval in 2011 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.

C-MET Non-Small Cell Lung Cancer Emerging Drugs Chapters

This segment of the C-MET Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

c-MET Non-Small Cell Lung Cancer Emerging Drugs

JNJ-61186372: Janssen Research & Development, LLCJNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen’s licensing agreement with Genmab for use of its Duo Body technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitortherapies.

• PLB1001 - Beijing Pearl Biotechnology Limited Liability Company

PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

C-MET Non-Small Cell Lung Cancer: Therapeutic Assessment

This segment of the report provides insights about the different C-MET Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in C-MET Non-Small Cell Lung Cancer

There are approx. 20+ key companies which are developing the therapies for C-MET Non-Small Cell Lung Cancer. The companies which have their C-MET Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, etc.

Phases

This report covers around 20+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

C-MET Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intramuscular
• Intratumoral
• Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Bispecific antibodies
• Immunotherapies
• Monoclonal antibodies
• Small molecules

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

C-MET Non-Small Cell Lung Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses C-MET Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-MET Non-Small Cell Lung Cancer drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence C-MET Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve C-MET Non-Small Cell Lung Cancer.

March 2020: Janssen announces U.S. FDA breakthrough therapy designation granted for JNJ-6372 for the treatment of Non-Small Cell Lung Cancer The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.

C-MET Non-Small Cell Lung Cancer Report Insights

• C-MET Non-Small Cell Lung Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

C-MET Non-Small Cell Lung Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing C-MET Non-Small Cell Lung Cancer drugs?
• How many C-MET Non-Small Cell Lung Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of C-MET Non-Small Cell Lung Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the C-MET Non-Small Cell Lung Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for C-MET Non-Small Cell Lung Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AbbVie
• Janssen Research & Development
• Beijing Pearl Biotechnology Limited Liability Company
• Novartis

Key Products

• Telisotuzumab
• JNJ-61186372
• PLB1001
• Glumetinib
• INC280
• EGF816
• APL-101
• PF-02341066